In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

Rodolfo A. Estrada; Diego J. Maselli; Antonio R. Anzueto

doi:10.7326/J23-0063

In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

Rodolfo A. Estrada, Diego J. Maselli, Antonio R. Anzueto

Division of Pulmonary Diseases

Producción científica: Comment/debate › revisión exhaustiva

1 Cita (Scopus)

Resumen

SOURCE CITATION: Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.

Idioma original	English (US)
Páginas (desde-hasta)	JC102
Publicación	Annals of internal medicine
Volumen	176
N.º	9
DOI	https://doi.org/10.7326/J23-0063
Estado	Published - sept 1 2023

ASJC Scopus subject areas

Internal Medicine

Acceder al documento

10.7326/J23-0063

Otros archivos y enlaces

Citar esto

@article{348879abbb5e48719204bb0525a7740b,

title = "In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations",

abstract = "SOURCE CITATION: Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.",

author = "Estrada, {Rodolfo A.} and Maselli, {Diego J.} and Anzueto, {Antonio R.}",

year = "2023",

month = sep,

day = "1",

doi = "10.7326/J23-0063",

language = "English (US)",

volume = "176",

pages = "JC102",

journal = "Annals of internal medicine",

issn = "0003-4819",

publisher = "American College of Physicians",

number = "9",

}

TY - JOUR

T1 - In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

AU - Estrada, Rodolfo A.

AU - Maselli, Diego J.

AU - Anzueto, Antonio R.

PY - 2023/9/1

Y1 - 2023/9/1

N2 - SOURCE CITATION: Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.

AB - SOURCE CITATION: Bhatt SP, Rabe KF, Hanania NA, et al; BOREAS Investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389;205-214.37272521.

UR - http://www.scopus.com/inward/record.url?scp=85171807572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171807572&partnerID=8YFLogxK

U2 - 10.7326/J23-0063

DO - 10.7326/J23-0063

M3 - Comment/debate

C2 - 37665985

AN - SCOPUS:85171807572

SN - 0003-4819

VL - 176

SP - JC102

JO - Annals of internal medicine

JF - Annals of internal medicine

IS - 9

ER -

In COPD with type 2 inflammation despite inhaled triple therapy, dupilumab safely reduced exacerbations

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto